List of Excipients in Branded Drug DOVONEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
LEO Pharma Inc	DOVONEX	calcipotriene	50222-260	.ALPHA.-TOCOPHEROL, DL-
LEO Pharma Inc	DOVONEX	calcipotriene	50222-260	CETETH-20
LEO Pharma Inc	DOVONEX	calcipotriene	50222-260	CETOSTEARYL ALCOHOL
LEO Pharma Inc	DOVONEX	calcipotriene	50222-260	DIAZOLIDINYL UREA
LEO Pharma Inc	DOVONEX	calcipotriene	50222-260	DICHLOROBENZYL ALCOHOL
LEO Pharma Inc	DOVONEX	calcipotriene	50222-260	EDETATE DISODIUM
LEO Pharma Inc	DOVONEX	calcipotriene	50222-260	GLYCERIN

Dovonex Excipient Strategy and Commercial Opportunities for Calcipotriene

Last updated: August 9, 2026

Dovonex is a topical calcipotriene product for plaque psoriasis. Its commercial opportunity is no longer based on primary-molecule exclusivity. The value is in vehicle performance, tolerability, adherence, combination therapy, manufacturing efficiency and differentiated topical delivery.

Calcipotriene is a synthetic vitamin D3 analog used at a very low concentration, typically 0.005%. Its formulation must control dose uniformity, chemical stability, skin deposition and local irritation while avoiding excessive systemic absorption. Generic and reformulated products can compete through cream feel, scalp usability, packaging, reduced mess, lower irritation and combination regimens.

What is Dovonex and which formulations contain calcipotriene?

Dovonex contains calcipotriene, also called calcipotriol outside the United States. U.S. Dovonex products have included ointment, cream and topical solution dosage forms. The active ingredient is used for plaque psoriasis and has also been incorporated into combination products with betamethasone dipropionate.[1-4]

Product type	Active ingredient	Typical strength	Primary use	Formulation opportunity
Dovonex ointment	Calcipotriene	0.005%	Plaque psoriasis	Occlusive delivery and high skin residence
Dovonex cream	Calcipotriene	0.005%	Plaque psoriasis	Better cosmetic acceptability and daily adherence
Dovonex topical solution	Calcipotriene	0.005%	Scalp and hair-bearing areas	Low-residue delivery and applicator control
Sorilux foam	Calcipotriene	0.005%	Plaque psoriasis	Rapid-spreading, cosmetically acceptable delivery
Calcipotriene/betamethasone products	Calcipotriene plus corticosteroid	Product-specific	Plaque psoriasis	Combination efficacy and regimen simplification

Dovonex is a prescription topical drug. Because calcipotriene is a small molecule, follow-on products use generic-drug pathways rather than biosimilar pathways. The principal U.S. regulatory route for a conventional generic is an abbreviated new drug application, or ANDA.

What excipients are used in Dovonex formulations?

Dovonex excipients vary by dosage form. The ointment is designed around an anhydrous, semi-solid base, while the cream uses an emulsion system and the solution uses a liquid vehicle suitable for scalp application.

Ointment excipient architecture

The Dovonex ointment formulation has used petrolatum and mineral-oil-type components, together with surfactant and humectant functionality. Public labeling identifies excipient systems including mineral oil, white petrolatum, polysorbate 80 and propylene glycol.[1]

The commercial advantages of an ointment include:

• High residence time on psoriatic plaques.
• Low water activity and relatively simple microbiological control.
• Strong occlusive behavior.
• Compatibility with low-dose, lipophilic or moderately lipophilic actives.

The disadvantages are predictable. Ointments are greasy, can stain clothing, are less attractive for daytime use and perform poorly on hair-bearing areas. A generic ointment can compete on spreadability, reduced drag, lower residue and improved tube dispensing without materially changing the active ingredient.

Cream excipient architecture

The cream is an oil-in-water or related emulsion system containing surfactants, fatty alcohols, glycols, mineral-oil components, buffering agents and purified water. The vehicle must maintain calcipotriene uniformity across the emulsion while controlling pH and preservative performance.[2]

Cream development priorities include:

1. Emulsion stability over the labeled shelf life.
2. Consistent delivery of 0.005% calcipotriene.
3. Low stinging on fissured or inflamed skin.
4. Rapid rub-in and low visible residue.
5. Compatibility with tubes, pumps and other packaging.

The main commercial advantage of a cream is patient acceptability. A product that feels materially less greasy than an ointment may improve use on large body-surface areas, even where pharmacological efficacy is comparable.

Solution excipient architecture

The scalp solution relies on volatile or semi-volatile solvent systems, cosolvents and pH control. A solution must prevent precipitation, maintain assay and limit crystallization after application. It also must avoid excessive hair wetting and residue.[3]

The most valuable solution attributes are:

• Precise drop or pump dosing.
• Low viscosity.
• Fast drying.
• Minimal hair clumping.
• Low alcohol-related sting.
• Packaging that limits evaporation and contamination.

The solution format has a clear commercial niche because psoriasis on the scalp is difficult to treat with ointments and conventional creams.

How should an excipient strategy be designed for calcipotriene?

A calcipotriene excipient strategy should begin with the target product profile rather than with a generic vehicle copied from an existing label. The best vehicle depends on the anatomical site, psoriasis severity, patient preference and intended claim.

Target product profile by body site

Target site	Preferred vehicle	Key excipient objective	Commercial positioning
Thick plaques on elbows or knees	Ointment or rich cream	Occlusion and skin residence	Efficacy and lower dosing frequency
Trunk and limbs	Light cream or lotion	Fast rub-in and lower residue	Adherence and body-surface coverage
Scalp	Solution, foam or low-residue spray	Hair penetration and rapid drying	Convenience and cosmetic acceptability
Intertriginous areas	Mild cream or low-irritant gel	Reduced sting and low occlusion	Sensitive-site usability
Large affected areas	Lotion, foam or pump cream	Spreadability and dose control	Lower application burden

Excipients with strategic value

Propylene glycol can act as a humectant and cosolvent, but it may contribute to irritation in some patients. A reformulated product could examine alternative glycols or lower glycol loading, provided calcipotriene solubility and delivery remain adequate.

Fatty alcohols and emulsifiers improve cream structure and spreadability. Their ratio can materially affect sensory properties, phase stability and drug release. A lower-wax system may reduce drag, while a higher-structure system may increase residence time.

Silicones can improve slip and reduce tack. Dimethicone and related materials may support a more cosmetically acceptable product, but their impact on drug release, emulsion stability and bioequivalence must be characterized.

Buffer systems are important because calcipotriene stability is formulation-dependent. The developer should map pH, temperature, light exposure, oxygen exposure and container interaction. A pH target that improves chemical stability may increase skin irritation or reduce preservative performance.

Preservatives are relevant for aqueous creams, lotions and solutions. The choice should account for microbial protection, irritation potential, preservative adsorption to packaging and compatibility with the active ingredient. Anhydrous or low-water systems can reduce preservative dependence.

Chelators and antioxidants may help manage trace-metal or oxidative pathways. They should be evaluated through forced-degradation studies rather than added as routine formulation components.

What formulation patents protect Dovonex and where are the white spaces?

The original calcipotriene compound and early formulation patents have largely moved beyond their principal commercial exclusivity periods. Current opportunity is therefore concentrated in new dosage forms, combination products, delivery systems, manufacturing processes and device-linked claims.

Patent risk should be assessed separately for four categories:

Patent category	Relevance to Dovonex competition	Strategic risk
Calcipotriene compound patents	Likely limited for conventional products	Low relative to vehicle patents
Basic ointment or cream patents	May affect older branded or licensed products	Usually manageable through design-around
Foam, spray, gel or advanced delivery patents	Can protect differentiated products	Moderate to high
Combination-product patents	Relevant to calcipotriene plus corticosteroid products	Product- and jurisdiction-specific

A new excipient system can generate patentable subject matter when it provides a defined technical result, such as improved stability, reduced crystallization, enhanced scalp deposition, reduced irritation or a specific pharmacokinetic profile. Broad claims covering “calcipotriene in a topical composition” are less likely to provide durable protection than claims tied to quantified excipient ranges, particle size, pH, water activity, delivery device or comparative performance.

The strongest patent strategy would combine:

• Composition claims.
• Use claims directed to treatment schedules or anatomical sites.
• Packaging or dispensing claims.
• Manufacturing claims covering homogenization, cooling, filling or crystallization control.
• Comparative data showing improved stability, reduced residue or better patient usability.

When does Dovonex lose exclusivity and what is the generic entry position?

Dovonex’s original small-molecule and dosage-form exclusivities are no longer the primary commercial barrier to calcipotriene generic entry. Generic calcipotriene ointment, cream and solution products have been marketed in the United States, confirming that the active ingredient is commercially accessible through the ANDA pathway.

The relevant exclusivity questions are now product-specific:

• Whether a particular Dovonex NDA remains listed as marketed.
• Whether current Orange Book patent listings remain active.
• Whether a follow-on product references the same dosage form and strength.
• Whether a new formulation requires an ANDA or a 505(b)(2) application.
• Whether a differentiated product has its own patent or regulatory exclusivity.

The Orange Book identifies approved products, patent listings and, where applicable, use codes. It does not establish that every listed patent will block approval or commercialization. A generic applicant can challenge listed patents through a Paragraph IV certification or wait for patent expiry.[5]

What is the Orange Book status of Dovonex?

Dovonex and calcipotriene reference products should be evaluated through the FDA Orange Book and Drugs@FDA records on an NDA-by-NDA basis. The critical diligence items are:

1. NDA status and whether the reference product is currently marketed.
2. Dosage-form-specific patent listings.
3. Pediatric exclusivity or other regulatory exclusivity.
4. Listed use codes for method-of-use patents.
5. Approved supplements that may affect formulation or labeling.
6. Whether the proposed generic matches the reference product’s inactive-ingredient profile.

The absence of meaningful remaining exclusivity for the original active ingredient does not eliminate formulation or combination-product risk. The most relevant potential barriers are product-specific patents on foams, gels, delivery systems and calcipotriene/betamethasone compositions.

Which companies are challenging Dovonex and what litigation affects the market?

The commercial challenge has primarily come from generic manufacturers and from branded competitors using alternative topical vehicles. The market includes manufacturers of generic calcipotriene ointments, creams and solutions, as well as developers of foam and combination products.

No biosimilar competition applies because calcipotriene is a chemically synthesized small molecule. The appropriate competitive framework is:

• ANDA-based generic entry.
• 505(b)(2) reformulation.
• Branded combination products.
• Pharmacy substitution.
• Dermatology-focused specialty distribution.
• Device or vehicle differentiation.

Paragraph IV activity is most relevant when a follow-on applicant targets a product with active Orange Book-listed patents. For older conventional calcipotriene products, the commercial question is less likely to be a compound-patent challenge and more likely to involve approval timing, manufacturing readiness, labeling, reimbursement and substitution.

How does Dovonex compare with calcipotriene/betamethasone products?

Combination products have a stronger commercial proposition than calcipotriene monotherapy because they address inflammation and keratinocyte proliferation with a single regimen. They also create more complex formulation and patent positions.

Attribute	Dovonex monotherapy	Calcipotriene/betamethasone combination
Active ingredients	Calcipotriene	Calcipotriene plus corticosteroid
Formulation complexity	Lower	Higher
Excipient challenge	Stability and topical delivery	Stability, compatibility and steroid control
Patent opportunity	Vehicle and delivery	Composition, regimen and dosage form
Generic substitution	Relatively direct	More product-specific
Commercial differentiation	Texture, adherence, site-specific delivery	Efficacy, regimen simplification and safety positioning

The combination market has included products such as Taclonex and Enstilar. Those products create a higher-value benchmark for foam, gel and emulsion technologies, but they also introduce greater patent and regulatory complexity.[4,6]

What commercial opportunities exist for new Dovonex-compatible vehicles?

The strongest opportunities are differentiated products that solve practical application problems.

Low-residue scalp foam or spray

A calcipotriene foam or spray could target scalp psoriasis and hair-bearing areas. The commercial value depends on fast drying, low residue, uniform dose delivery and patient preference. Foam technology may support premium pricing, although manufacturing, propellant selection and device testing increase development cost.

Non-greasy body lotion

A lotion or light emulsion could compete with ointments for large affected areas. The formulation must preserve calcipotriene stability at lower viscosity and maintain adequate deposition after rapid rub-in.

Sensitive-skin cream

A product with reduced solvent load, low fragrance exposure and a carefully controlled preservative system could target patients who discontinue topical therapy because of burning or irritation. Claims would need clinical support.

Pump or metered-dose packaging

Packaging can create value without changing the active ingredient. Metered delivery may improve dosing consistency, reduce contamination and support body-surface-area instructions. Device claims and human-factors data may provide additional intellectual-property value.

Fixed-dose combination reformulation

A new vehicle for calcipotriene plus betamethasone could target improved stability, reduced application frequency or lower residue. This opportunity has higher development and patent risk but also greater pricing potential.

What manufacturing and intellectual-property barriers apply?

Calcipotriene is used at a very low concentration, making content uniformity a central manufacturing risk. The process must control:

• API dispersion and dissolution.
• Homogenization energy.
• Temperature during compounding.
• Cooling rate.
• Particle formation or recrystallization.
• Bulk hold time.
• Tube or pump filling accuracy.
• Light and oxygen exposure.
• Extractables and leachables.

For emulsions, scale-up can change droplet size, viscosity and drug release. For foams, the active must remain uniformly distributed through the base and the final container must deliver consistent actuation. For solutions, evaporation and precipitation during storage or use are key risks.

The most defensible manufacturing patents are likely to cover a repeatable process parameter set linked to a measurable product result. Trade secrets may be more effective than patents for mixing order, temperature profiles and filling conditions when reverse engineering is difficult.

What generic launch risks exist for Dovonex?

A conventional generic calcipotriene product faces several launch risks:

Risk	Impact
Bioequivalence failure	Delays approval and increases formulation work
Inactive-ingredient mismatch	May require additional safety justification
Irritation or sensitization	Can undermine substitution and prescribing
Poor cosmetic profile	Reduces adherence and repeat use
Low reimbursement	Compresses price and margin
Manufacturing scale-up failure	Creates supply interruption
Patent or use-code dispute	Can delay approval or launch
Limited pharmacy demand	Reduces commercial return

For ANDA products, formulation similarity and performance are critical. A product with a technically acceptable vehicle but poor patient experience may lose share to branded foam, combination therapy or other topical classes.

How strong is the Dovonex patent estate?

The original Dovonex estate is commercially weaker than an estate built around a recently launched novel topical platform. The active ingredient is mature, conventional calcipotriene products face generic competition, and the principal defensible value now lies in dosage-form-specific innovation.

A new entrant can improve its position by securing patents around:

• Stable low-dose calcipotriene emulsions.
• Low-irritation solvent systems.
• Scalp-directed delivery.
• Foam or spray packaging.
• Calcipotriene and corticosteroid compatibility.
• Defined treatment regimens.
• Manufacturing controls that prevent recrystallization.

Geographic coverage should prioritize the United States, European Union, United Kingdom, Japan, Canada and major psoriasis markets. Patent term, patentability standards and regulatory linkage differ across those jurisdictions. U.S. Orange Book listing is commercially important, while European enforcement generally depends on national validation and litigation.

Key Takeaways

• Dovonex is a mature calcipotriene topical product; primary-molecule exclusivity is not the main commercial barrier.
• Excipient value lies in stability, skin deposition, tolerability, spreadability and adherence.
• Ointments support residence time but have cosmetic disadvantages.
• Creams offer the broadest opportunity for improved patient acceptability.
• Solutions and foams have the clearest differentiation potential for scalp and hair-bearing areas.
• Calcipotriene is a small molecule, so generic competition applies rather than biosimilar competition.
• The strongest new patent opportunities concern vehicles, combination products, devices and manufacturing processes.
• Calcipotriene/betamethasone products offer greater commercial differentiation but carry higher formulation and patent risk.
• Generic launch economics depend heavily on vehicle quality, reimbursement, manufacturing reliability and substitution behavior.

FAQs About Dovonex Excipient and Commercial Strategy

Is propylene glycol essential in Dovonex formulations?

No. Propylene glycol can support cosolvency and moisturization, but its necessity depends on the dosage form, target concentration, stability profile and alternative solvent system.

Can a company launch a new calcipotriene foam through an ANDA?

Only if the product meets the applicable requirements for pharmaceutical equivalence and bioequivalence to the reference product. A materially different foam may require a 505(b)(2) application rather than a conventional ANDA.

Does Dovonex have biosimilar competition?

No. Calcipotriene is a chemically synthesized small molecule. Follow-on competition is handled through generic-drug and reformulation pathways.

Which packaging format has the strongest commercial potential?

Metered pumps, low-residue foams and scalp applicators have the strongest differentiation potential because they can improve dosing control and usability. The optimal format depends on the target anatomical site.

Can a new excipient combination receive patent protection?

Yes, if the formulation is novel, non-obvious and supported by credible technical data. Patent strength improves when defined excipient ranges are linked to unexpected stability, delivery, irritation or usability benefits.

References

1. U.S. Food and Drug Administration. (n.d.). Dovonex (calcipotriene) ointment prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Dovonex (calcipotriene) cream prescribing information. Drugs@FDA.

3. U.S. Food and Drug Administration. (n.d.). Dovonex (calcipotriene) topical solution prescribing information. Drugs@FDA.

4. U.S. Food and Drug Administration. (n.d.). Enstilar (calcipotriene and betamethasone dipropionate) foam prescribing information. Drugs@FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

6. U.S. Food and Drug Administration. (n.d.). Taclonex (calcipotriene and betamethasone dipropionate) prescribing information. Drugs@FDA.